Location Greater New York Area, United States, North America Regions East Coast Gender Male
Investor Type
LinkedIn View on LinkedIn
Mark Chin is the Board of Director at Ottimo Pharma. He attended Wharton School .
Overview
Partner Investments
Announced Date | Organization Name | Investor Name | Lead Investor | Funding Round | Money Raised |
|---|---|---|---|---|---|
 Ottimo Pharma |  Avoro Capital Advisors | Series A - Ottimo Pharma | |||
 Vicebio |  Avoro Ventures | Series B - Vicebio | |||
 Evommune |  Arix Bioscience | Series B - Evommune | |||
 Ensoma | Arix Bioscience | Series B - Ensoma | |||
 Disc Medicine | Arix Bioscience | Post-IPO Equity - Disc Medicine | |||
Disc Medicine | Arix Bioscience | Post-IPO Equity - Disc Medicine | |||
 VelosBio | Arix Bioscience | Series B - VelosBio | |||
 Imara | Arix Bioscience | Series B - Imara | |||
 Harpoon Therapeutics | Arix Bioscience | Series C - Harpoon Therapeutics | |||
VelosBio | Arix Bioscience | Series A - VelosBio |
Organization Name | Title At Company | Start Date | End Date |
|---|---|---|---|
 Gilead Sciences | |||
 The Boston Consulting Group | |||
 Longitude Capital | |||
Arix Bioscience |
Board and Advisor Roles
- Aura Biosciences
Board Member 
ImaraBoard Member - Depixus
Board Member - Vicebio
Board Member - Iterum Therapeutics
Board Of Director
Education
Recent News and Activity
There is no recent news or activity for this profile.
